Ticker Scorecard - ALLO Basics Company: Allogene Therapeutics, Inc. IPO Date: October 8, 2018 Sector: Healthcare Industry: Biotech Market Cap: $438.21M Activated in VL: True Average Daily Range Avg Daily Range: $0.49 | 3.02% Avg Daily Range (30 D): $0.07 | 3.32% Avg Daily Range (90 D): $0.10 | 3.82% Institutional Daily Volume Avg Daily Volume: 1.28M Avg Daily Volume (30 D): 2.42M Avg Daily Volume (90 D): 2.06M Trade Size Avg Trade Size (Sh.): 120 Avg Trade Size (Sh.) (30 D): 243 Avg Trade Size (Sh.) (90 D): 201 Institutional Trades Total Inst.Trades: 2,839 Avg Inst. Trade: $1.88M Avg Inst. Trade (30 D): $1.32M Avg Inst. Trade (90 D): $1.31M Avg Inst. Trade Volume: .16M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.46M Avg Closing Trade (30 D): $1.34M Avg Closing Trade (90 D): $1.25M Avg Closing Volume: 220.94K     News Dec 26, 2024 @ 4:26 PM Oncology in Focus: How Emerging Therapies Are Resh... Source: Prnewswire Oct 22, 2024 @ 5:00 PM Gene Therapy Clinical Trial Pipeline Gains Momentu... Source: Delveinsight Sep 10, 2024 @ 8:51 AM Gene Editing Therapeutics Market Forecast 2024-202... Source: Researchandmarkets.Com Jul 1, 2024 @ 12:30 PM Allogene Therapeutics Activates Three Community Ca... Source: Allogene Therapeutics, Inc. Jun 20, 2024 @ 12:30 PM Allogene Therapeutics Initiates Pivotal Phase 2 Tr... Source: Allogene Therapeutics, Inc. Financials   TTM Q2 2024 Q1 2024 Basic EPS $-.32 $-.35 $-.38 Diluted EPS $-.32 $-.35 $-.38 Revenue $ M $ M $ .02M Gross Profit $ $ $ Net Income / Loss $ -66.29M $ -66.36M $ -65M Operating Income / Loss $ -71.77M $ -71.43M $ -69.5M Cost of Revenue $ $ $ Net Cash Flow $ -119.43M $ 119.63M $ -32.12M PE Ratio